TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects.
about
Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognitionNicotine receptors and depression: revisiting and revising the cholinergic hypothesisDrug Development in Alzheimer's Disease: The Contribution of PET and SPECTMolecules and circuits involved in nicotine addiction: The many faces of smokingTargeting α4β2 nicotinic acetylcholine receptors in central nervous system disorders: perspectives on positive allosteric modulation as a therapeutic approach.Nicotine receptor subtype-specific effects on auditory evoked oscillations and potentialsNegative affective states and cognitive impairments in nicotine dependenceNicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disordersMouse models for studying genetic influences on factors determining smoking cessation success in humans.Augmentation of cognitive function by NS9283, a stoichiometry-dependent positive allosteric modulator of α2- and α4-containing nicotinic acetylcholine receptors.Nicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitizationPredictors of early abstinence in smokers with schizophreniaChemistry and pharmacological characterization of novel nitrogen analogues of AMOP-H-OH (Sazetidine-A, 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol) as α4β2-nicotinic acetylcholine receptor-selective partial agonists.Role of neuronal nicotinic acetylcholine receptors (nAChRs) on learning and memory in zebrafish.Recent developments in novel antidepressants targeting α4β2-nicotinic acetylcholine receptors.Pharmacokinetics and safety profile of ispronicline (TC-1734), a new brain nicotinic receptor partial agonist, in young healthy male volunteers.Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers.Alzheimer's disease and age-related memory decline (preclinical)The catecholaminergic-cholinergic balance hypothesis of bipolar disorder revisited.Microdialysis as a tool in local pharmacodynamics.Dissociation between duration of action in the forced swim test in mice and nicotinic acetylcholine receptor occupancy with sazetidine, varenicline, and 5-I-A85380.Identification of novel α4β2-nicotinic acetylcholine receptor (nAChR) agonists based on an isoxazole ether scaffold that demonstrate antidepressant-like activity.It is not "either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and moodNicotinic receptors in neurodegeneration.Intracerebral microdialysis technique and its application on brain pharmacokinetic-pharmacodynamic study.Neuronal nicotinic receptors as novel targets for inflammation and neuroprotection: mechanistic considerations and clinical relevance.Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: an overview of preclinical and clinical findings.Can small molecules provide truly effective enhancement of cognition? Current achievements and future directions.In vivo brain microdialysis: advances in neuropsychopharmacology and drug discovery.Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.Allosteric modulators of α4β2 nicotinic acetylcholine receptors: a new direction for antidepressant drug discovery.Nicotine Addiction and Psychiatric Disorders.Targeting the Cholinergic System to Develop a Novel Therapy for Huntington's DiseaseVarenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect.The effect of varenicline on the development and expression of nicotine-induced behavioral sensitization and cross-sensitization in rats.Antidepressant-like effects of nicotinic acetylcholine receptor antagonists, but not agonists, in the mouse forced swim and mouse tail suspension tests.A randomized double-blind study comparing 25 and 50 mg TC-1734 (AZD3480) with placebo, in older subjects with age-associated memory impairment.Effects of AZD3480, a neuronal nicotinic acetylcholine receptor agonist, and donepezil on dizocilpine-induced attentional impairment in rats.
P2860
Q24614080-803ECE31-D8E3-49AF-8A69-919032376AA6Q24634536-9B8B557A-D2E5-4E3F-9FB9-DA496FA81F7EQ26749755-3D509110-E105-4337-AD7D-D4B931F2056FQ27008063-A8F210D5-78F0-46F2-B9A8-EC520DC43A4CQ27693356-1AC57950-86C1-4CF1-977B-3488CA289444Q28728978-51039949-4167-4CEC-8470-F923DB38A573Q30371220-7D2B4860-C168-4BB8-B243-B4D09D6ED6E2Q30372351-52BC841F-485F-4697-89C4-798B4BC57187Q30432964-4FDCEBBA-5AEE-4305-9FAB-CDD60E0C5833Q30449856-A3C2B0DF-BE9E-45DA-B386-6F23D6FB8DF8Q30475334-737999E0-3662-4EF8-8B25-23381636A53FQ33679772-C7A832D1-375E-4F24-8E47-F03FC24541D6Q34215376-995BA0E3-375A-422D-BBE4-C341CCC58C9DQ34390062-BD5CADCC-A570-4B48-99AC-691F8C7EAE79Q34394190-9FB472F4-83D1-43F8-BF11-36FCBE367835Q34543205-619F73D1-1564-4599-BAE0-8C42CC288BD8Q34602337-FC6ACB44-1C5E-43D8-8EA7-5E50059478DCQ35041190-1A4A3A8A-6EEA-46EE-AEA5-00FDBAD03D27Q35054681-BF99BE4B-6C93-43A3-AD82-E712815D0143Q35594859-1BBBCF5A-A3D9-4FEF-9A46-358A4256897EQ35699233-2F064AD7-A992-4699-B09C-6B4B270E542CQ35738694-54F532AD-651B-4207-BEFE-8FC94ACA9ABDQ36666651-6A74C61D-F696-46D1-B906-6FB72E1FFBD3Q36828916-3082B76B-8BF0-4F65-BB3D-B7ADE396C1D2Q37078257-6BD759E9-F094-450C-8652-7D80F5F0AFFAQ37508584-88F8896C-58A8-4B2F-A391-F4464875ED53Q37826637-4D57E649-10BE-48BC-B62D-C08D92A6EEACQ37867702-D1735965-7501-45E0-ACA2-B4C4C958F050Q37870701-9EDE3704-0F94-4F2C-8B36-64B6C72309CEQ38022265-51F76B3C-FB14-4B31-9C9E-E2CEFF4093EEQ38063303-FA588D20-9075-4EAA-95F7-88F38891B570Q38608639-731216EE-B5CF-421D-A764-5EECBC1D8F71Q39041214-44D3834E-A191-4FDF-B561-A4596BE17F23Q42112960-6C054E6D-2429-42C2-B37B-A712C6A99E10Q44650026-5E430195-1E60-43F6-9872-A3E0ED54BC18Q46516278-8E100311-391D-47F5-9EE3-9AB94B021D5DQ48168007-743D971C-5B98-490F-BF24-3782116B65B2Q51344595-4EC96DE0-049E-48A8-8EF4-BFF4F0EDD816
P2860
TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
TC-1734: an orally active neur ...... ong-lasting cognitive effects.
@ast
TC-1734: an orally active neur ...... ong-lasting cognitive effects.
@en
TC-1734: an orally active neur ...... ong-lasting cognitive effects.
@nl
type
label
TC-1734: an orally active neur ...... ong-lasting cognitive effects.
@ast
TC-1734: an orally active neur ...... ong-lasting cognitive effects.
@en
TC-1734: an orally active neur ...... ong-lasting cognitive effects.
@nl
prefLabel
TC-1734: an orally active neur ...... ong-lasting cognitive effects.
@ast
TC-1734: an orally active neur ...... ong-lasting cognitive effects.
@en
TC-1734: an orally active neur ...... ong-lasting cognitive effects.
@nl
P2093
P1476
TC-1734: an orally active neur ...... long-lasting cognitive effects
@en
P2093
G Andrees Bohme
Geoffrey Dunbar
Gregory J Gatto
Laurent Pradier
M Carmen Obinu
Merouane Bencherif
Michel Laville
Michel Reibaud
Sharon R Letchworth
Vincent M Traina
P304
P356
10.1111/J.1527-3458.2004.TB00010.X
P577
2004-01-01T00:00:00Z